Munich, Germany

Michael Lehnerer



 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 22(Granted Patents)


Company Filing History:


Years Active: 2009-2013

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Michael Lehnerer: Innovator in Recombinant Protein Production

Introduction

Michael Lehnerer is a notable inventor based in Munich, Germany. He has made significant contributions to the field of biotechnology, particularly in the production of recombinant proteins. With a total of 2 patents, his work has advanced the understanding and application of human blood coagulation factors.

Latest Patents

Lehnerer's latest patents include innovative methods for processing recombinant human G-CSF precursor and recombinant blood clotting factors. The first patent focuses on a G-CSF precursor that comprises a signal peptide and a G-CSF peptide, incorporating specific mutations to enhance its functionality. The second patent presents an improved method for producing recombinant human blood clotting factors, specifically factor VIII and factor IX. This invention utilizes an immortalized human cell line to stably express viral transcription activator proteins, which are linked to a vector that codes for blood coagulating factors.

Career Highlights

Throughout his career, Michael Lehnerer has worked with prominent companies in the biotechnology sector, including Octagene GmbH and Octapharma AG. His expertise in recombinant protein production has positioned him as a valuable asset in the industry.

Collaborations

Lehnerer has collaborated with several professionals in his field, including Carola Schröder and Charlotte Hauser. These partnerships have contributed to the successful development of his patented technologies.

Conclusion

Michael Lehnerer is a distinguished inventor whose work in recombinant protein production has made a significant impact in biotechnology. His innovative patents and collaborations reflect his commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…